It's PRIMETIME. Postoperative Avoidance of Radiotherapy: Biomarker Selection of Women at Very Low Risk of Local Recurrence

Kirwan, Cliona C.; Kilburn, Lindsey; Fox, Louis; Cheang, Maggie C.U.; Griffin, C; Francis, Ashleigh M.; Kirby, Anna M.; Ah-See, Mei-Lin W.; Sharma, Ram A.; Mukesh, M.; Twyman, N.; Loane, Joseph; Dodson, Andrew; Provenzano, Elena; Kunkler, Ian; Yarnold, John; Pharoah, Paul D.P.; Caldas, Carlos; Stobart, Hilary; Turner, Lesley; Megias, D.; Bliss, Judith M.; Coles, C.E.

doi:10.1016/j.clon.2016.06.007

Cited by 71 publications

(58 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two large studies are also underway in the United Kingdom (PRIMETIME, a single-arm study) and in Australia/New Zealand (EXPERT, a randomized trial that will likely open in late 2017) (33,34). In the PRIMETIME study, the risk groups will be determined according to IHC4þclinical, a refinement of IHC phenotyping that combines the protein expression of ER, PR, HER2, and Ki67 with clinicopathologic parameters (35). After BCS, eligible women (>60 years old, stage T1N0, grade 1 or 2, and ERþPRþHER2À) with very, very low IHCþ4 scores will be recommended to omit RT.…”

Section: Hrd Her2l Breast Cancermentioning

confidence: 99%

Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy

Horton

Jagsi

Woodward

et al. 2018

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Hrd Her2l Breast Cancermentioning

confidence: 99%

Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy

Horton

Jagsi

Woodward

et al. 2018

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Where next for UK breast radiotherapy research? The collaborations established over the years from the previous breast radiotherapy trials continue to expand and strengthen in ongoing trials of dose modulation for highrisk patients (IMPORT-High [15]), 5 day hypofractionation (FAST-Forward [16]) and omission of radiotherapy in patients at very low risk of recurrence (PRIMETIME [17]). For all of these trials, the aim is to reduce side-effects while maintaining local tumour control.…”

Section: Contents Lists Available At Sciencedirectmentioning

confidence: 99%

The IMPORT LOW Trial: Collaborative Research Accelerates Practice Change in Breast Radiotherapy

et al. 2019

View full text Add to dashboard Cite

“…Avoidance of radiotherapy may be possible in some patient groups, particularly in light of the findings of the CALGB 9343 trial, which has confirmed low rates of ipsilateral recurrence at 10 years in patients ≥ 70 years of age with hormone receptor positive node negative tumours under 5cm treated with adjuvant hormone therapy alone after wide local excision 63 . This question is being addressed by the ongoing PRIMETIME study 64 .…”

Section: Adjuvant Radiotherapymentioning

confidence: 99%

Opportunities and priorities for breast surgical research

Cutress

McIntosh

Potter

et al. 2018

The Lancet Oncology

View full text Add to dashboard Cite

Background: The Breast Cancer Campaign Gap analysis (2013) established breast cancer research priorities without specific focus on surgical research nor the role of surgeons. The majority of breast cancer patients encounter a surgeon at diagnosis or during treatment, thus surgical involvement in design and delivery of high-quality research to improve patient care is critical. This review aims to identify opportunities and priorities for breast surgical research to complement the previous gap analysis. Methods: Research-active breast surgeons met and identified topic areas for breast surgical research which mapped to the patient pathway. These included diagnosis, neoadjuvant treatment, surgery, adjuvant therapy and special groups (e.g. risk-reducing surgery). Section leads were identified based on research interests with invited input from experts in specific areas, supported by consultation with the Association of Breast Surgery (ABS) membership and Independent Cancer Patients' Voice (ICPV). The document was iteratively modified until participants were satisfied that key priorities for surgical research were clear. Results: Key research gaps were identified for each topic area including: (1) issues surrounding overdiagnosis and treatment; (2) optimising selection for neoadjuvant therapies and subsequent surgery; (3) reducing re-operation rates for breast conserving surgery; (4) generating evidence for the clinical and cost-effectiveness of breast reconstruction and mechanisms for evaluating novel interventions; (5) determining optimal axillary management, especially post-neoadjuvant treatment; (6) defining and standardising indications for risk-reducing surgery. Strategies for resolving these knowledge gaps are proposed. Conclusions: Surgeons are ideally placed for a central role in breast cancer research and should foster a culture of engagement and participation in research to benefit patients and the NHS. Development of infrastructure and surgical research capacity together with appropriate allocation of research funding will be needed to successfully address the key clinical and translational research gaps highlighted in this analysis within the next two decades.

show abstract

It's PRIMETIME. Postoperative Avoidance of Radiotherapy: Biomarker Selection of Women at Very Low Risk of Local Recurrence

Cited by 71 publications

References 9 publications

Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy

Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy

The IMPORT LOW Trial: Collaborative Research Accelerates Practice Change in Breast Radiotherapy

Opportunities and priorities for breast surgical research

Contact Info

Product

Resources

About